Figure 7
From: Systemic Administration of siRNA via cRGD-containing Peptide
In vivo biodistributions of the complexes in C57BL/6 mice (2.5 mg/kg for siRNA).
(a) Whole body imaging at given time points after administration via tail vein injection. (b) Fluorescence detection of isolated main organs of mice at the final observation time point. (c) Quantitative analysis of (b) using a molecular imaging software package (Carestream Health, USA). The data were normalized to corresponding tissues from saline-treated animals. Each bar represents the mean ± SEM of three independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 vs. corresponding tissue from naked siRNA-treated mice.
